We present an 8 years old girl who was diagnosed at 6 months of age of Progressive Familial Intrahepatic Cholestasis type 2. Although liver transplantation (LT) was classically considered curative for these patients, cholestasis recurrence with normal gamma-glutamyl transpeptidase (GGT), mediated by anti-bile salt export pump (BSEP) antibodies after LT (auto-antibody Induced BSEP Deficiency, AIBD) has been recently reported. Our patient underwent LT at 14 months. During her evolution, patient presented three episodes of acute rejection. Seven years after the LT, the patient presented pruritus with cholestasis and elevation of liver enzymes with persistent normal GGT. Liver biopsy showed intrahepatic cholestasis and giant-cell transformation with very low BSEP activity. Auto-antibodies against BSEP were detected therefore an AIBD was diagnosed. She was treated with Rituximab and immunoadsorption with resolution of the AIBD. As a complication of the treatment she developed a pneumocystis infection successfully treated with corticoids, cotrimoxazol and anidulafungin.

**ABSTRACT**

We present an 8 years old girl who was diagnosed at 6 months of age of Progressive Familial Intrahepatic Cholestasis type 2. Although liver transplantation (LT) was classically considered curative for these patients, cholestasis recurrence with normal gamma-glutamyl transpeptidase (GGT), mediated by anti-bile salt export pump (BSEP) antibodies after LT (auto-antibody Induced BSEP Deficiency, AIBD) has been recently reported. Our patient underwent LT at 14 months. During her evolution, patient presented three episodes of acute rejection. Seven years after the LT, the patient presented pruritus with cholestasis and elevation of liver enzymes with persistent normal GGT. Liver biopsy showed intrahepatic cholestasis and giant-cell transformation with very low BSEP activity. Auto-antibodies against BSEP were detected therefore an AIBD was diagnosed. She was treated with Rituximab and immunoadsorption with resolution of the AIBD. As a complication of the treatment she developed a pneumocystis infection successfully treated with corticoids, cotrimoxazol and anidulafungin.

**Keywords:** Cholestasis, progressive familial intrahepatic 2; Liver transplantation; Child
features of PFIC2 include elevated bile salts in plasma with important reduction in bile and persistently normal gamma-glutamyl transpeptidase (GGT). Histologically, it is characterized by lobular cholestasis with diffuse giant cell transformation of hepatocytes. In most cases, immunohistochemistry studies of BSEP show an absence of BSEP expression at the canalicular membrane [4]. The liver disease caused by BSEP deficiency without response to medical treatment and the increased risk of hepatic malignancy makes liver transplantation (LT) the only solution for most of these patients [2,5].

Although LT was classically considered curative for these BSEP patients, cholestasis recurrence with normal GGT, mediated by anti-BSEP antibodies after LT (auto-antibody Induced BSEP Deficiency, AIBD) has been recently reported [6-8]. These patients presented a phenotypic PFIC2 recurrence with not only biochemical but also histological features of primary BSEP deficiency [8]. It is hypothesized that patients with ABCB11 mutations causing a complete lack of BSEP expression in the native liver, derived in a lack of tolerance and anti-BSEP antibodies production after LT [7]. In severe forms, liver retransplantation is usually needed [9]. Rituximab is a chimeric monoclonal antibody against CD20, which is broadly used in hematologic malignancies and inflammatory conditions. Here we report a case of successful treatment of AIBD in an eight-year-old child using Rituximab and ten consecutive sessions of immunoabsorption. We will also highlight the potentially different clinical implications of BSEP antibodies, the possible complications related to Rituximab treatment and the need of some precautions.

This study was performed according to the guidelines of the Declaration of Helsinki and written informed consent was provided by the parents of the patient. All investigations on hepatobiliary transporters including human tissue or serum samples as presented in this study were approved by the ethical review committee of the Hospital Vall d’Hebron in Barcelona.

CASE REPORT

An infant girl of six months presented with severe pruritus refractory to medical treatment, a blood test showing elevated liver enzymes and bilirubin, and persistent low GGT. A mass spectrometry assay of the urine ruled out an inborn error of bile acids synthesis. At three months of age, a liver biopsy was performed showing micronodular liver cirrhosis with intrahepatic cholestasis and gigantocellular transformation. Immunohistochemistry for BSEP performed in liver tissue showed no BSEP expression. Genetic testing using the PFIC panel NextGeneDx (Imegen, Valencia, Spain) revealed a homozygotic pathogenic mutation (c. 1062T>A) that produces a premature stop codon [10]. The patient developed an end-stage liver disease and underwent a LT at 14 months of age. Transplant immunosuppression was induced with tacrolimus, corticoids and basiliximab. During her evolution, patient presented three episodes of biopsy proven acute rejection (BPAR) with elevated liver enzymes and GGT with normal bilirubin and bile acids (30, 54, and 70 months post-LT). All three episodes were solved after corticoids pulses and tacrolimus levels optimization. After the second BPAR, autoimmunity assessment showed high titers (1/640) of auto-antibodies against the bile canaliculi with an anti-Liver Kidney Microsoma-like pattern. Histology of the three episodes was compatible with cellular acute rejection with normal BSEP immunohistochemistry. In March 2017, the patient presented pruritus with cholestasis (maximum bilirubin of 14.3 mg/dL) and elevation of liver enzymes (maximum of aspartate aminotransferase 555 and alanine aminotransferase 523 UI/L) with persistent normal GGT. With the suspicion of AIBD, a liver
biopsy was performed which showed intrahepatic cholestasis and giant-cell transformation with very low BSEP expression assessed by immunochemistry assay. Although none of the typical autoantibodies was observed, high titers of anti-Liver-Kidney Microsome (LKM) like antibodies were again detected. A Western Blot analysis showed that these anti-LKM like antibodies were directed against BSEP ([6,8]). To perform the Western Blot assay, hepatocellular polarized cells from rats that expresses only a minimal level of BSEP (Can 10) [11], were transfected with a BSEP<sup>WT</sup>-green fluorescent protein (GFP) plasmid using Fugene Xtrem HP (Roche Diagnostics, Meylan, France) as previously reported [12]. Subsequently, primary antibodies used for immunostaining were incubated for 1 hour at 37°C (mouse anti-GFP; 1/80: Roche Diagnostics) and patient serum (1/100 to 1/500). Cells were rinsed and incubated with the appropriate Alexa-conjugated secondary antibodies (1/1,000; Molecular Probes, Eugene, OR, USA). The coverslips, were examined with a Zeiss Axioskop epifluorescence microscope (Carl Zeiss, Jena, Germany). Sera from patient liver transplanted for another indication than a PFIC2 were used as a negative control.

With the diagnostic of AIBD, Rituximab at a dose of 375 mg/m² was started and 10 sessions of immunoadsorption (TheraSorb-LIFE 18; Miltenyi Biotec, Bergisch Gladbach, Germany) were performed, decreasing the levels of liver enzymes, bile and biliary acids to their basal, nearly normal levels. The anti-BSEP titers decreased from 1/1,280 to 1/80, remaining positive despite treatment. Two months after the last Rituximab dose, the patient was admitted to our Unit because she presented dyspnoea and oxygen desaturation. Despite normal chest radiography, a CT-scan was performed observing a bilateral and diffuse pulmonary parenchymatous affection in frosted glass pattern compatible with *pneumocystis* infection. In the bronchoalveolar wash *pneumocystis jirovecii* was detected by real-time polymerase chain reaction and direct immunofluorescence. Initially, the patient was treated using respiratory...
support with high flow nasal cannula, 2 mg/kg/day of corticoids and cotrimoxazol. After one week of cotrimoxazol treatment, clinical worsening with higher dyspnoea and oxygen requirements was observed. A second bronchoalveolar wash was performed that once again was only positive for *pneumocystis jirovencii*. Anidulafungin was added to the treatment because of its synergic effect with cotrimoxazol for treating severe *pneumocystis* pneumonia [13]. From there on the patient showed progressive improvement. After four weeks of cotrimoxazol and three of anidulafungin treatment, the patient was discharged from our hospital with prophylactic cotrimoxazol treatment and nearly normal liver function.

**DISCUSSION**

In 2009, the first case post-LT anti-BSEP alloimmunization was reported [8]. After this first published case, less than 15 cases have been reported, evidencing it is a very rare condition. Many other genetic liver diseases need LT to be solved, but PFIC2 is the unique disease among them for which an anti-body mediated recurrence has been described. The mechanism of this recurrence is not fully understood. It is believed that severe ABCB11 mutations that carry extremely low expression of BSEP in the canaliculi of the native liver are needed to explain the lack of tolerance of the BSEP epitopes by the transplant recipient. But not all patients reported with severe mutations presented disease recurrence, possibly because BSEP-proteins act as sequestered antigens due to its intrahepatocyte localization. In some cases, these proteins can make contact with the host’s immune system, especially during rejection, vascular thrombosis or ischemia-reperfusion injury. Thereby after the LT, antibodies against the normal BSEP-protein expressed by the allograft can be produced, carrying a phenotypical recurrence of the disease. In fact, BSEP recurrence can be regarded as a specific form of acute antibody mediated rejection in which the Donor Specific Antibodies are directed against BSEP. The conditions needed to develop AIBD can explain the different time lapses from LT to diseases recurrence observed between patients. In our case, it seems reasonable to think that after three BPAR episodes, BSEP epitopes were exposed, activating an antibody response. However, anti-BSEP antibodies were observed during the second episode of high GGT rejection. It is not clear why these antibodies did not initially produce liver damage or whether after the third rejection, more pathogenic anti-BSEP antibodies were produced. Although the phenotypic presentation of the BSEP recurrence is the same, it is possible that the mechanism trough which it develops is different depending on which epitope the antibody is against, therefore producing different degrees of disease. The diverse pathogenicity of the anti-BSEP antibodies could also explain the different severity observed between the reported patients. The importance of the case is mainly increase the awareness about the possibility of recurrence of the disease in PFIC2 transplanted patients. AIBD should be suspected in PFIC2 transplanted patients presenting pruritus, cholestasis and normal GGT. The suspicion should be stronger in patients with severe mutations especially after episodes of liver damage such as rejection or vascular thrombosis. The liver biopsy could reveal histological alterations similar to those found in the diagnosis, and the confirmation should be performed using Western Blot.

In some mild cases, an immunosuppression optimization is enough to decrease the production of anti-BSEP antibodies [6]. However, severe forms must be treated more aggressively in order to save the transplanted liver. Combination of immunoadsorption and Rituximab has been previously published to be effective to remove anti-BSEP antibodies [14]. In our case, two doses of weekly Rituximab and ten immunoadsorption sessions were very
Effective in reducing anti-BSEP titers and improving clinically and biochemically our patient. Rituximab is a monoclonal antibody that binds to CD20 antigen depleting B lymphocytes. Most of our understanding of host defense against *Pneumocystis* has focused on T lymphocytes being almost exclusively observed in human immunodeficiency virus (HIV) patients. Although the mechanism by which Rituximab is a risk factor for *Pneumocystis* is not known, the mortality in non-HIV Rituximab treated patients is still higher than in HIV, having more atypical presentations with a fulminant course [15]. In our patient, a rapid detection and aggressive treatment with combination therapy (cotrimoxazol plus anidulafingin) was needed to achieve infection resolution. Precaution in non-HIV immunosuppressed patients, as solid organ receptors, should be taken into account when using Rituximab, assessing case by case the need of cotrimoxazol prophylaxis.

In conclusion, AIBD should be suspected in PFIC2 transplanted patients presenting pruritis, cholestasis and normal GGT. In severe cases, combination with Rituximab and immunoadoption is an effective treatment for treating AIBD patients, but long term results are lacking. Although Rituximab is a key part of this approach, precaution against *Pneumocystis* infection with cotrimoxazol prophylaxis should be considered.

**REFERENCES**

1. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998;20:233-8. [PUBMED | CROSSREF]

2. Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerová D, Rayner A, Dutton L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 2008;134:1203-14. [PUBMED | CROSSREF]

3. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 2009;4:1. [PUBMED | CROSSREF]

4. Jansen PL, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GI, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 1999;117:1370-9. [PUBMED | CROSSREF]

5. Alissa FT, Jaffe R, Shneider BL. Update on progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2008;46:241-52. [PUBMED | CROSSREF]

6. Jara P, Hierro L, Martínez-Fernández P, Alvarez-Doforno R, Yáñez F, Díaz MC, et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med 2009;361:1359-67. [PUBMED | CROSSREF]

7. Maggiore G, Gonzales E, Sciveres M, Redon MJ, Grosse B, Stieger B, et al. Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2. J Hepatol 2010;53:984-6. [PUBMED | CROSSREF]

8. Keitel V, Burdelski M, Warskulat U, Kühlkamp T, Keppler D, Häussinger D, et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005;41:1160-72. [PUBMED | CROSSREF]

9. Keitel V, Burdelski M, Vojnisek Z, Schmitt L, Häussinger D, Kubitz R. De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis. Hepatology 2009;50:510-7. [PUBMED | CROSSREF]

https://pghn.org

https://doi.org/10.5223/pghn.2020.23.2.174
10. Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology 2010;51:1645-55.

11. Cassio D, Macias RI, Grosse B, Marin JJ, Monte MJ. Expression, localization, and inducibility by bile acids of hepatobiliary transporters in the new polarized rat hepatic cell lines, Can 3-1 and Can 10. Cell Tissue Res 2007;330:447-60.

12. Gonzales E, Grosse B, Schuller B, Davit-Spraul A, Conti F, Guettier C, et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology 2015;62:558-66.

13. Tu GW, Ju MJ, Xu M, Rong RM, He YZ, Xue ZG, et al. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients. Nephrology (Carlton) 2013;18:736–42.

14. Kubitz R, Dröge C, Kluge S, Stross C, Walter N, Keitel V, et al. Autoimmune BSEP disease: disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis. Clin Rev Allergy Immunol 2015;48:273-84.

15. Martin-Garrido I, Carmona EM, Specks U, Limper AH. Pneumocystis pneumonia in patients treated with rituximab. Chest 2013;144:258-65.